ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

被引：0

作者：

Flinn, Ian W.

Jacobson, Caron Alyce

Nastoupil, Loretta J.

Morschhauser, Franck

Davies, Andrew

Buske, Christian

Corradini, Paolo

Guillermo, Armando Lopez

Reshef, Ran

Parameswaran, Vinod

Sehgal, Alison

Tees, Michael Timothy

Lui, Christine

Xue, Wei

Beygi, Sara

Grechko, Nikolay

Bolsue, Pisita

Giovanetti, Alessandro

To, Christina Ann

Nahas, Myrna

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[2] Dana Farber Canc Inst, Boston, MA USA

[3] MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Lille, Ctr Hosp Univ, Lille, France

[5] Univ Southampton, Southampton Expt Canc Med Ctr, Southampton, Hants, England

[6] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] Univ Barcelona, Barcelona, Spain

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Avera Med Grp Hematol Transplant & Cellular Thera, Sioux Falls, SD USA

[11] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA

[12] Colorado Blood Canc Inst, Denver, CO USA

[13] Kite, Santa Monica, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7579

引用

页数：1

共 50 条

[31] Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.
Westin, Jason
Oluwole, Olalekan O.
Kersten, Marie Jose
Miklos, David Bernard
Perales, Miguel-Angel
Ghobadi, Armin
Rapoport, Aaron
Sureda, Anna
Jacobson, Caron Alyce
Farooq, Umar
van Meerten, Tom
Ulrickson, Matthew L.
Elsawy, Mahmoud
Leslie, Lori A.
Chaganti, Sridhar
Dickinson, Michael
Yang, Yin
Schupp, Marco Andreas
To, Christina Ann
Locke, Frederick L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[32] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
Ball, G.
Kuruvilla, J.
Boodoo, C.
Jain, M. D.
VALUE IN HEALTH, 2021, 24 : S39 - S39
[33] ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) plus Utomilumab Patients with Refractory Large B Cell Lymphoma
Reshef, Ran
Miklos, David B.
Timmerman, John M.
Jacobson, Caron A.
Bennani, Nabila N.
Rossi, John M.
Sherman, Marika
Zheng, Lianqing
Sun, Jennifer
Palluconi, Gabrielle
Kim, Jenny J.
Jain, Michael D.
BLOOD, 2019, 134
[34] Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.
Westin, Jason
Oluwole, Olalekan O.
Kersten, Marie Jose
Miklos, David Bernard
Perales, Miguel-Angel
Ghobadi, Armin
Rapoport, Aaron
Sureda, Anna
Jacobson, Caron Alyce
Farooq, Umar
van Meerten, Tom
Ulrickson, Matthew L.
Elsawy, Mahmoud
Leslie, Lori A.
Chaganti, Sridhar
Dickinson, Michael
Yang, Yin
Schupp, Marco Andreas
To, Christina Ann
Locke, Frederick L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA107 - LBA107
[35] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD OF CARE FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AS 4TH OR LATER LINE TREATMENT IN SWEDEN
Eklund, O.
Kanje, V. Hedlof
Doble, B.
Cervin, K.
VALUE IN HEALTH, 2023, 26 (12) : S155 - S155
[36] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
Diakite, I
Lin, V. W.
Klijn, S.
Navale, L.
Purdum, A. G.
Fenwick, E.
Botteman, M.
van Hout, B.
VALUE IN HEALTH, 2019, 22 : S41 - S41
[37] Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent NonHodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial
Neelapu, Sattva S.
Chavez, Julio C.
Sehgal, Alison R.
Epperla, Narendranath
Ulrickson, Matthew L.
Bachy, Emmanuel
Munshi, Pashna N.
Casulo, Carla
Maloney, David G.
de Vos, Sven
Reshef, Ran
Leslie, Lori A.
Oluwole, Olalekan O.
Yakoub-Agha, Ibrahim
Khanal, Rashmi
Rosenblatt, Joseph D.
Peng, Weixin
Lui, Christine
Wulff, Jacob
Shen, Rhine R.
Poddar, Soumya
Lee, Andrew
Miao, Harry
Nikolajeva, Olga
Jacobson, Caron A.
BLOOD, 2023, 142
[38] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Lee, Dasom
Kambhampati, Swetha
Bobillo, Maria Silvina Odstrcil
Adedokun, Babatunde
Shadman, Mazyar
Olson, Amanda L.
Herrera, Alex F.
Lee, Catherine J.
Jacobson, Caron A.
Bye, Matthew
Hamadani, Mehdi
Kim, Soyoung
Dahiya, Saurabh
Hu, Zhen-Huan
Speth, Kelly
To, Christina
Mirjah, Debbie L.
Best, Timothy
Locke, Frederick L.
Ahmed, Nausheen
Tees, Michael T.
Pasquini, Marcelo C.
Ahmed, Sairah
BLOOD, 2024, 144 : 527 - 528
[39] CLINICAL PREDICTORS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS
Sanderson, R.
Munoz, J.
Wang, Y.
Kanters, S.
Limbrick-Oldfield, E.
Miao, H.
Spooner, C.
Baro, E.
Xu, H.
Jacobson, C.
VALUE IN HEALTH, 2022, 25 (12) : S47 - S48
[40] Health Utilities for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL): Ad Hoc Analysis From an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study
Lin, Vincent W.
Jiang, Yizhou
Chuang, Ling Hsiang
Navale, Lynn
Cheng, Paul
Purdum, Anna
BONE MARROW TRANSPLANTATION, 2018, 53 : 879 - 879

← 1 2 3 4 5 →